Landmark Bio Breaks Ground

A Boston-area collaboration on advanced life-sciences techniques

Ran Zheng

Ran Zheng

Photograph courtesy Kris Snibbe/Harvard University

Construction began today on a state-of-the-art biomanufacturing facility in a 40,000-square-foot leased space at the Watertown Arsenal, a few miles west of Harvard Square, culminating a several-year process of developing a Boston-area research collaborative. Ran Zheng, a veteran of the biotechnology industry, has been appointed CEO of the company, which will help develop emerging cell- and gene-based therapies for human use. Founded and led by Harvard, MIT, Cytiva (formerly part of GE Healthcare Life Sciences), FUJIFILM Diosynth Biotechnologies, and Alexandria Real Estate (a developer of labs and offices), the company was recently renamed Landmark Bio (formerly, the Center for Advanced Biological Innovation and Manufacturing). Five Harvard-affiliated hospitals—Brigham and Women’s, Massachusetts General Hospital, the Dana-Farber Cancer Institute, Boston Children’s, and Beth Israel Deaconess Medical Center—are collaborating institutions, together with the Massachusetts Life Sciences Center. (MilliporeSigma, a provider of industrial and lab chemicals, is apparently no longer formally involved.)

Zheng, a chemical engineer by training, has extensive experience in biotechnology process development, including Good Manufacturing Practices (GMP), a U.S. Food and Drug Administration certification necessary for most human therapies that is recognized by pharmaceutical companies and regulatory agencies worldwide. In addition to GMP manufacturing capacity (including the ability to create mRNA therapies delivered in lipid nanoparticles—an approach made famous by the Moderna and Pfizer coronavirus vaccines), the facility will include innovation and process development laboratories that will help researchers from academic, healthcare, and industry partners turn their research discoveries and laboratory protocols into products for human use. Warehouse space will be used to store patient and healthy donor materials, as well as therapeutic products destined for clinical testing.

Harvard provost Alan M. Garber, who chairs the board of Landmark Bio and has led the multi-institution collaboration that created it (see “Accelerating Cell Manufacture”), said in a statement that Zheng is “a leader with broad and deep industry expertise and an impressive record of achievement in technology development and global clinical development….The kickoff today on the construction of Landmark Bio’s state-of-the-art facility is just the first step in our collective efforts to innovate in biological manufacturing”—part of Harvard’s efforts to strengthen what is perceived as one of the nation’s leading biomedical and biotechnology research centers. 

Although biological therapies are harder to develop than chemical therapies, they are approximately twice as likely to receive regulatory approval as typical small-molecule drugs (which are taken orally, in pill form).

Updated 8-17-2021 to reflect that Cytiva was just a part of GE Healthcare Life Sciences, not the entire enterprise.

Read more articles by Jonathan Shaw

You might also like

The Faculty of Arts and Sciences Zeroes In on the Classroom Experience

Class schedules and academics are at the top of the agenda for Harvard faculty.

Harvard Football: Harvard 59, Holy Cross 24

Another week, another blowout, this one against an in-state rival

Trump Says a Deal with Harvard Is Close

Administration squeezes Harvard finances, and a federal judge blasts deportation efforts as unconstitutional.

Most popular

What Trump Means for John Roberts’s Legacy

Executive power is on the docket at the Supreme Court.

Three Harvardians Win Macarthur Fellowships

A mathematician, a political scientist, and an astrophysicist are honored with “genius” grants for their work.

This Harvard Scientist Is Changing the Future of Genetic Diseases

David Liu has pioneered breakthroughs in gene editing, creating new therapies that may lead to cures.

Explore More From Current Issue

Student walking under bright stage lights shaped like smartphones displaying social media apps.

Two Years of Doxxing at Harvard

What happens when students are publicly named and shamed for their views?

Renaissance portrait of young man thought to be Christoper Marlowe with light beard, wearing ornate black coat with gold buttons and red patterns.

Shakespeare’s Greatest Rival

Without Christopher Marlowe, there might not have been a Bard.

Two people moving large abstract painting with blue V-shaped design in museum courtyard.

A Harvard Art Museums Painting Gets a Bath

Water and sunlight help restore a modern American classic.